Medicine for Chronic Dry Eye Syndrome
| Reference number | |
| Coordinator | Redwood Pharma AB |
| Funding from Vinnova | SEK 349 000 |
| Project duration | July 2013 - January 2014 |
| Status | Completed |
Important results from the project
Objectives: 1) test the safety of the company´s new eye preparation consisting of an active ingredient and formulated using new types of polymers, and 2) create a new patent application. In vitro assays where our product formulation was tested on cow corneas showed that it did not produce any negative effects. This positive result supports our continued development work, and will serve us well in discussions with potential partners. Meanwhile, the company has met our second objective. With the help of patent attorneys, we have developed a first draft of a new patent.
Expected long term effects
The results of our safety tests demonstrate that the product most likely will not produce any adverse effects when given to humans and as well as that it has considerable value and reduced risk to new investors. The results will help attract more investors. With the new patent application, the company will be able to build more value in the firm by strengthening its patent portfolio. Patents are important to the company and its investors who want to invest in a secured innovation that prevents others from developing similar, competing products.
Approach and implementation
Our original plan has been kept. Both in vitro tests and the new patent will help to raise the company´s value and attractiveness. Our efforts to move on and find new investors should be facilitated with these developments. We have achieved a lot for the company using VINN NU funds from Vinnova.